Heart failure is a global public health problem that affects more than 26 million people
worldwide. The global burden of heart failure is growing and is expected to increase …

The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of
hormones possessing relevant haemodynamic and anti-remodelling actions in the …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

The natriuretic peptides are important tools to establish diagnosis and prognosis in heart
failure (HF). With application of therapies for HF, changes in both B-type natriuretic peptide …

Abstract Background: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker
Intensified Treatment in Heart Failure) trial demonstrated that a strategy to “guide” …

Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a
powerful cardiovascular biomarker for a number of disease states, specifically heart failure …

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. HF with
preserved ejection fraction (HFpEF) is a complex syndrome, often participated by several …

Peptides have been studied for over 100 years, but for most of this time the focus was on a
specific peptide or peptides, and not on the general peptidome of a biological sample. In the …

One of the main challenges in the development of new analytical platforms for ultrasensitive
bioaffinity detection is jointly achieving a wide dynamic range in target analyte …

Heart failure is a class of cardiovascular diseases that remains the number one cause of
death worldwide with a substantial economic burden of around $18 billion incurred by the …